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Molting in decapod crustaceans is controlled by molt-inhibiting hormone (MIH), an eyestalk 31	  
neuropeptide that suppresses production of ecdysteroids by a pair of molting glands (Y-organs or 32	  
YOs). Eyestalk ablation (ESA) activates the YOs, which hypertrophy and increase ecdysteroid 33	  
secretion. At mid premolt, which occurs 7-14 days post-ESA, the YO transitions to the 34	  
committed state; hemolymph ecdysteroid titers increase further and the animal reaches ecdysis 35	  
~3 weeks post-ESA. Two conserved signaling pathways, mechanistic target of rapamycin 36	  
(mTOR) and transforming growth factor-β (TGF-β), are expressed in the Gecarcinus lateralis 37	  
YO. Rapamycin, an mTOR antagonist, inhibits YO ecdysteroidogenesis in vitro. In this study, 38	  
rapamycin lowered hemolymph ecdysteroid titer in ESA G. lateralis in vivo; levels were 39	  
significantly lower than in control animals at all intervals (1 to 14 days post-ESA). Injection of 40	  
SB431542, an activin TGF-β receptor antagonist, lowered hemolymph ecdysteroid titers 7 and 41	  
14 days post-ESA, but had no effect on ecdysteroid titers at 1 and 3 days post-ESA. mRNA 42	  
levels of mTOR signaling genes Gl-mTOR, Gl-Akt, and Gl-S6k were increased by 3 days post-43	  
ESA; the increases in Gl-mTOR and Gl-Akt mRNA levels were blocked by SB431542. Gl-44	  
elongation factor 2 and Gl-Rheb mRNA levels were not affected by ESA, but SB431542 45	  
lowered mRNA levels at Days 3 and 7 post-ESA. The mRNA level of an activin TGF-β peptide, 46	  
Gl-myostatin-like factor (Mstn), increased 5.5-fold from 0 to 3 days post-ESA, followed by a 50-47	  
fold decrease from 3 to 7 days post-ESA. These data suggest that (1) YO activation involves an 48	  
up regulation of the mTOR signaling pathway; (2) mTOR is required for YO commitment; and 49	  
(3) a Mstn-like factor mediates the transition of the YO from the activated to the committed 50	  




1. Introduction 53	  
Control of molting in crustaceans involves a complex interaction between the eyestalk 54	  
neurosecretory center, which produces inhibitory neuropeptides, such as molt-inhibiting 55	  
hormone (MIH) and crustacean hyperglycemic hormone (CHH), and a pair of molting glands (Y-56	  
organs or YOs) in the anterior cephalothorax (Chang and Mykles, 2011; Hopkins, 2012; 57	  
Webster, 2015). MIH maintains the YO in the basal state during intermolt (stage C4) through a 58	  
cyclic nucleotide second messenger pathway (Chang and Mykles, 2011; Covi et al., 2009, 2012). 59	  
A reduction in MIH activates the YO and triggers the transition from intermolt to premolt (stage 60	  
D0). Molting is induced by eyestalk ablation (ESA) or multiple leg autotomy in many decapod 61	  
species, including Gecarcinus lateralis (Chang and Mykles, 2011; Mykles, 2001). The activated 62	  
YO hypertrophies to increase molting hormone (ecdysteroids) synthetic capacity (Chang and 63	  
Mykles, 2011; Mykles, 2011). The YO remains sensitive to MIH, CHH, and other factors, so that 64	  
premolt processes can be temporally suspended by stress or injury (e.g., limb bud autotomy or 65	  
LBA) (Chang and Mykles, 2011; Mykles, 2001; Nakatsuji et al., 2009; Yu et al., 2002). By mid 66	  
premolt (stage D1-2), the YO transitions to the committed state, in which ecdysteroid production 67	  
increases further and the YO becomes insensitive to MIH, CHH, and LBA (Chang and Mykles, 68	  
2011; Mykles, 2001; Nakatsuji et al., 2009). Increased phosphodiesterase (PDE) activity 69	  
contributes to the reduced response to MIH by keeping intracellular cyclic nucleotides low 70	  
(Chang and Mykles, 2011; Nakatsuji et al., 2009). By the end of premolt (stage D3-4), high 71	  
ecdysteroids initiate the transition from the committed state to the repressed state; hemolymph 72	  
ecdysteroid titers drop precipitously and the animal molts (Chang and Mykles, 2011; Mykles, 73	  
2011).  74	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The signaling pathways that drive the changes in the YO during the premolt period are 75	  
poorly understood. In insects, the insulin/mechanistic target of rapamycin (mTOR) signal 76	  
transduction pathway regulates prothoracic gland (PG) growth and ecdysteroidogenic capacity 77	  
(see (Danielsen et al., 2013; Nijhout et al., 2014; Rewitz et al., 2013; Yamanaka et al., 2013) for 78	  
reviews). mTOR is a protein kinase highly conserved among the Metazoa that functions as a 79	  
sensor for cellular growth regulation by nutrients, cellular energy status, oxygen level, and 80	  
growth factors (Albert and Hall, 2015; Cetrullo et al., 2015; Laplante and Sabatini, 2013). 81	  
Prothoracicotropic hormone (PTTH) and insulin-like peptides (ILPs) activate mTOR, which 82	  
phosphorylates p70 S6 kinase (S6K) and eIF4E-binding protein to increase global translation of 83	  
mRNA into protein (Smith et al., 2014; Teleman, 2010; Yamanaka et al., 2013). FK506-binding 84	  
protein 12 complexes with rapamycin to inhibit mTOR (Hausch et al., 2013). Binding of ILP to a 85	  
membrane receptor activates a signal transduction cascade involving PI3K, PDK1, and Akt 86	  
protein kinases (Teleman, 2010). mTORC1 is activated by Rheb-GTP and is inactivated when 87	  
Rheb-GTPase activating protein (Rheb-GAP or tuberous sclerosis complex 1/2) promotes the 88	  
hydrolysis of GTP to GDP by Rheb (Huang and Manning, 2008). Phosphorylation by Akt 89	  
inactivates Rheb-GAP; the higher Rheb-GTP levels keep mTOR in the active state (Teleman, 90	  
2010). Over-expressing Rheb-GAP inhibits PG growth, while over-expressing PI3K, an 91	  
upstream activator of Akt, stimulates PG growth (Colombani et al., 2005; Layalle et al., 2008; 92	  
Mirth et al., 2005). In addition, inhibition of PI3K and mTOR blocks the PTTH-dependent 93	  
increase in ecdysteroid secretion in the PG (Gu et al., 2012; Gu et al., 2011). In G. lateralis, 94	  
rapamycin inhibits YO ecdysteroid secretion in vitro and the expression of Gl-mTOR and Gl-Akt 95	  
is increased in animals induced to molt by multiple leg autotomy, suggesting that mTOR 96	  
signaling is involved in YO activation (Abuhagr et al., 2014b). 97	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The transforming growth factor-β (TGF-β) superfamily is mediated by Smad transcription 98	  
factors that regulate genes through transcriptional activation or repression (Heldin and 99	  
Moustakas, 2012; Macias et al., 2015; Xu et al., 2012). TGFβ/Smad signaling controls PTTH-100	  
stimulated ecdysteroidogenesis in the insect PG (Rewitz et al., 2013; Yamanaka et al., 2013). 101	  
Disruption of activin (Actb) signaling in Drosophila blocks the metamorphic molt by preventing 102	  
the ecdysteroid peak by PTTH (Gibbens et al., 2011). Activin is required for the PG to respond 103	  
to PTTH; animals do not molt until they have achieved a critical weight (Rewitz et al., 2013). An 104	  
activin-like peptide may have a similar function in crustaceans, as the committed YO shows a 105	  
sustained constitutive increase in ecdysteroid synthesis and reduced sensitivity to MIH (Chang 106	  
and Mykles, 2011; Nakatsuji et al., 2009).  107	  
The components of the mTOR and TGF-β signaling pathways are well represented in the G. 108	  
lateralis YO transcriptome (Das et al., 2016). The purpose of this study is to investigate the roles 109	  
of mTOR and TGF-β signaling in regulating YO ecdysteroidogenesis. ESA was used to induce 110	  
molting in G. lateralis. The effects of rapamycin, an mTOR inhibitor, on hemolymph 111	  
ecdysteroid titer and of SB431542, an activin receptor antagonist, on ecdysteroid titer and gene 112	  
expression in vivo were determined. Hemolymph ecdysteroid titer was quantified by competitive 113	  
ELISA. mRNA levels of Gl-elongation factor 2 (Gl-EF2), Gl-myostatin-like factor (Gl-Mstn), 114	  
Gl-mTOR, Gl-Rheb, Gl-Akt, and Gl-S6k were quantified by quantitative polymerase chain 115	  
reaction (qPCR). The results suggest that mTOR and activin signaling control YO 116	  
ecdysteroidogenesis during premolt.   117	  
 118	  
  119	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2. Materials and methods 120	  
2.1. Animals and experimental treatments 121	  
Adult blackback land crabs, G. lateralis, were collected in the Dominican Republic, shipped 122	  
via commercial air cargo to Colorado, USA, and maintained as described previously (Covi et al., 123	  
2010). Molting was induced by eyestalk ablation (Covi et al., 2010; MacLea et al., 2012).  124	  
The effects of SB431542 and rapamycin were determined in vivo. At Day 0, intermolt G. 125	  
lateralis were ES-ablated and received a single injection of 10 mM SB431542 (Selleck 126	  
Chemicals, Houston, TX, USA) or 10 mM rapamycin (Selleck Chemicals) in dimethyl sulfoxide 127	  
(DMSO; ~10 µM estimated final hemolymph concentration) or dimethyl sulfoxide (DMSO; 128	  
~0.1% estimated final hemolymph concentration). Intact intermolt animals also received 129	  
SB431542 or DMSO. The injection volume was based on an estimated hemolymph volume of 130	  
30% of the wet weight. It was calculated using the equation: g wet weight × 0.3 μl 10 mM 131	  
SB431542, 10 mM rapamycin, or DMSO. YOs were harvested at 0, 1, 3, 5 (Gl-Mstn only), 7, 132	  
and 14 days post-injection, frozen in liquid nitrogen, and stored at -80 ˚C. Hemolymph samples 133	  
(100 µl) were taken at the time of tissue harvesting, mixed with 300 µl methanol, and 134	  
ecdysteroid was quantified by ELISA (Abuhagr et al., 2014a).  135	  
 136	  
2.2. Expression of mTOR signaling genes in Y-organ 137	  
Total RNA was isolated from YOs using TRIzol reagent (Life Technologies, Carlsbad, CA) 138	  
as described previously (Covi et al., 2010). First-strand cDNA was synthesized using 2 µg total 139	  
RNA in a 20 µl total reaction with SuperScript III reverse transcriptase (Life Technologies) and 140	  
oligo-dT(20)VN primer (50 µmol/l; IDT, Coralville, IA) as described (Covi et al., 2010).  141	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A LightCycler 480 thermal cycler (Roche Applied Science, Indianapolis, IN) was used to 142	  
quantify levels of Gl-EF2 (GenBank AY552550), Gl-Mstn (EU432218), Gl-mTOR (HM989973), 143	  
Gl-Rheb (HM989970), Gl-Akt (HM989974), and Gl-S6k (HM989975) mRNAs (Covi et al., 144	  
2008, 2010; MacLea et al., 2012). Reactions consisted of 1 µl first strand cDNA or standard, 5 µl 145	  
2× SYBR Green I Master mix (Roche Applied Science), 0.5 µl each of 10 mM forward and 146	  
reverse primers synthesized by Integrated DNA Technologies (IDT; Coralville, Iowa; Table 1), 147	  
and 3 µl nuclease-free water. PCR conditions were as follows: an initial denaturation at 95 ºC for 148	  
5 min, followed by 45 cycles of denaturation at 95 ˚C for 10 s, annealing at 62 ˚C for 20 s, and 149	  
extensions at 72 ˚C for 20 s, followed by melting curve analysis of the PCR product. Transcript 150	  
concentrations were determined with the LightCycler 480 software (Roche, version 1.5) using a 151	  
series of dsDNA gene standards produced by serial dilutions of PCR product for each gene (10 152	  
ag/µl to 10 ng/µl). The absolute amounts of transcript in copy numbers per µg of total RNA in 153	  
the cDNA synthesis reaction were calculated based on the standard curve and the calculated 154	  
molecular weight of dsDNA products.   155	  
 156	  
2.3. Statistical analyses and software 157	  
Statistical analysis was performed using JMP 12.1.0 (SAS Institute, Cary, NC). Means were 158	  
compared using one-way analysis of variance (ANOVA), both within and between treatments.  159	  
Post-hoc Tukey tests were additionally used to compare means over time within a treatment 160	  
group. Data are presented as mean ± 1 S.E. and the level of significance for the all of the data 161	  
analyses was set at α = 0.05. All qPCR data was log transformed to reduce the variance of the 162	  
mean. The data were graphed using QtiPlot 0.9.9-rc16 (Ion Vasilief, Romania) and adjusted 163	  




3. Results 166	  
3.1. Effects of rapamycin on YO ecdysteroidogenesis  167	  
Hemolymph ecdysteroid titers are a function of YO ecdysteroid synthetic activity (Chang 168	  
and Mykles, 2011; Mykles, 2011). ESA caused a significant increase in hemolymph ecdysteroid 169	  
titer in control animals (vehicle only), starting at 1 day post-ESA (Fig. 1). At 7-14 days post-170	  
ESA the animal transitions from early premolt (stage D0) to mid premolt (stage D1) (Covi et al., 171	  
2010), resulting in a large increase in hemolymph ecdysteroid titer from 7 days post-ESA to 14 172	  
days post-ESA (Fig. 1). A single injection of rapamycin at Day 0 blocked the ESA-induced 173	  
increase in hemolymph ecdysteroid titer, starting at 1 day post-ESA (Fig. 1). Titers increased 174	  
from Day 3 to Day 14 post-ESA, but the titers were significantly lower than those in control 175	  
animals at 1, 3, 7, and 14 days post-ESA (Fig. 1).  176	  
 177	  
3.2. Effects SB431542 on YO ecdysteroidogenesis and gene expression 178	  
Intact and ESA animals were injected with SB431542 or DMSO at Day 0 and hemolymph 179	  
and YOs were harvested 1, 3, 7, and 14 days post-injection. There was no effect of SB431542 or 180	  
DMSO on hemolymph ecdysteroid titers in intact intermolt animals (Fig. 2A). ESA animals 181	  
injected with DMSO showed a significant increase in hemolymph ecdysteroid titers by 1 day 182	  
post-ESA; titers continued to increase as the animal progressed through the premolt stage (Fig. 183	  
2A). SB431542 had no effect on the initial increase in ecdysteroid titer at 1 and 3 days post-ESA, 184	  
paralleling the increase in the control ESA animals (Fig. 2A). However, ecdysteroid titers in 185	  
SB431542-injected ESA animals at 7 and 14 days post-injection were significantly lower than 186	  
those of the control ESA animals (Fig. 2A). The ecdysteroid titer at 14 days post-ESA was 187	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higher than that at 7 days post-ESA, which indicates some recovery from the effects of the 188	  
reagent (Fig. 2A). 189	  
ESA-induced increases in YO gene expression in control animals was blunted by 190	  
SB431542. Gl-mTOR, Gl-Akt, and Gl-S6K mRNA levels were increased in control animals by 3 191	  
days post-ESA (Fig. 2C, E, F). The increases from Day 0 and Day 3 were 5.9-fold for Gl-mTOR; 192	  
1.3-fold for Gl-Akt, and 7.2-fold for Gl-S6K; the 2.4-fold increase for Gl-Rheb was not 193	  
significant (P = 0.25). There was no significant effect of ESA on Gl-EF2 and Gl-Rheb mRNA 194	  
levels in control animals (Fig. 2B, D). In contrast to the control ESA animals, gene expression in 195	  
YOs from SB431542-injected ESA animals either did not change significantly (Gl-EF2, Gl-196	  
mTOR, Gl-Akt, and Gl-S6k; Fig. 2B, C, E, F) or decreased (Gl-Rheb; Fig. 2D) at 3 days post-197	  
ESA. At Day 1, there were no significant differences in the means of all five genes between the 198	  
control and SB431542 ESA animals (Fig. 2B-F). The means of the Gl-EF2, Gl-mTOR, and Gl-199	  
Rheb mRNA levels between control and SB431542 ESA animals were significantly different at 3 200	  
days and 7 days post-ESA (Fig. 2B, C, D). The means of the Gl-Akt mRNA levels were 201	  
significantly different at 3 days post-ESA (Fig. 2E). There were no significant differences in the 202	  
means of the Gl-S6k mRNA levels between control and experimental treatments at all time 203	  
intervals (Fig. 2F). The transcript levels between control and experimental treatments converged 204	  
at 14 days post-ESA for all five genes (Fig. 2B-F). In intact animals, SB431542 had no effect on 205	  
gene expression (data not shown). 206	  
 207	  
3.3. Effects of ESA on expression of Gl-Mstn 208	  
Gl-myostatin-like factor (Gl-Mstn) is an activin-like member of the TGF-β family (Covi et 209	  
al., 2008). It was expressed in all 11 tissues examined, including the YO (Fig. 3). Gl-Mstn is the 210	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only activin-like contig identified in the G. lateralis YO transcriptome (Das et al., 2016). 211	  
Moreover, as SB431542 blocked the effects of ESA, Gl-Mstn mRNA level was quantified to 212	  
assess its role in the timing of the transition of the activated YO in early premolt to the 213	  
committed YO in mid premolt. Animals were ES-ablated and injected with DMSO (~0.1% final 214	  
concentration) at Day 0 to replicate the control treatment in the rapamycin and SB431542 215	  
injection experiments. YOs were harvested 0 to 14 days post-ESA; a 5-day post-ESA was added 216	  
for greater temporal resolution before the early to mid premolt transition. ESA resulted in a 217	  
significant increase in ecdysteroid titer by 3 days post-ESA, but there was no further increase in 218	  
titers at 7 and 14 days post-ESA, as observed in the controls in the rapamycin/DMSO and 219	  
SB431542/DMSO injection experiments (compare Fig. 4A with Figs. 1 and 2A). ESA had little 220	  
effect on Gl-EF2 mRNA level; the only significant difference was between the means at 1 day 221	  
and 14 days post-ESA (Fig. 4B). By contrast, Gl-Mstn mRNA increased 5.5-fold to its highest 222	  
level at 3 days post-ESA, then decreased 50-fold over the next 4 days to its lowest level at 7 days 223	  
post-ESA (Fig. 4C). By 14 days post-ESA, the Gl-Mstn mRNA level was comparable to that at 224	  
1, 3, and 5 days post-ESA, but was significantly higher than the level at Day 0 (Fig. 4C). 225	  
 226	  
4. Discussion 227	  
The highly conserved mTOR signaling pathway is found in all metazoans and has an 228	  
important role as a nutrient sensor critical for growth and development in insects (Albert and 229	  
Hall, 2015; Danielsen et al., 2013; Yamanaka et al., 2013). mTOR mediates the PTTH-induced 230	  
increase in ecdysteroid synthesis and secretion by the insect PG that triggers molting (Nijhout et 231	  
al., 2014). mTOR signaling appears to have an analogous role in the crustacean YO. Rapamycin 232	  
and cycloheximide inhibit ecdysteroid secretion by YOs in vitro (Abuhagr et al., 2014b; Mattson 233	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and Spaziani, 1986; Mattson and Spaziani, 1987). In G. lateralis induced to molt by MLA, 234	  
mRNA levels of Gl-mTOR, Gl-Akt, and Gl-EF2 are increased at premolt stages (Abuhagr et al., 235	  
2014b). Acute withdrawal of MIH by ESA increased mRNA levels of Gl-mTOR, Gl-Akt, and Gl-236	  
S6K in control animals (Fig. 2C, E, F). These data suggest that mTOR-dependent protein 237	  
synthesis is required for sustained ecdysteroid synthesis in both the insect and crustacean molting 238	  
glands. 239	  
In this study, rapamycin blocked YO ecdysteroidogenesis in vivo. As the YO cannot store 240	  
ecdysteroids, the hemolymph ecdysteroid titer is a function of YO ecdysteroidogenic activity 241	  
(Chang and Mykles, 2011; Mykles, 2011). Molting was induced by ESA and animals were 242	  
injected with a single dose of rapamycin or vehicle (DMSO) at Day 0. Hemolymph samples were 243	  
taken at 0, 1, 3, 7, and 14 days post-ESA and hemolymph ecdysteroid was quantified by ELISA. 244	  
Compared to the control, rapamycin blocked the increase in ecdysteroid titer and the effect lasted 245	  
for the duration of the experiment (Fig. 1). The prolonged effect of a single injection of 246	  
rapamycin was probably due to the low solubility of rapamycin in aqueous solutions. A 10 mM 247	  
rapamycin solution in 100% DMSO was used to keep injection volumes small, so that the final 248	  
DMSO concentration in the hemolymph did not exceed 0.1%. DMSO at concentrations of 2% 249	  
and 6% can inhibit YO ecdysteroid secretion (Spaziani et al., 2001). It is likely that much of the 250	  
rapamycin precipitated at the injection site and apparently took at least 2 weeks to re-dissolve. 251	  
The sustained release of rapamycin from the injection site inhibited YO ecdysteroidogenesis and 252	  
prevented, or at least delayed, the further increase in hemolymph ecdysteroid titer from Day 7 to 253	  
Day 14 post-ESA observed in the control animals (Fig. 1). The higher mean and greater 254	  
variability in ecdysteroid titer at Day 14 post-ESA in the rapamycin-injected animals suggest that 255	  
the effect of the drug was beginning to dissipate as the rapamycin was being cleared from the 256	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animals (Fig. 1). These data suggest that mTOR activity is required for YO activation and 257	  
increased ecdysteroid synthesis during the premolt stage. Moreover, mTOR activity appears to 258	  
be necessary for the transition of the YO from the activated to committed state. 259	  
The YO undergoes a critical change in physiological properties during the premolt period. 260	  
In early premolt the activated YO remains sensitive to MIH, CHH, limb autotomy factor - 261	  
proecdysis (LAFpro), and possibly other signals to suspend molting under unfavorable conditions 262	  
(Chang and Mykles, 2011; Nakatsuji et al., 2009; Yu et al., 2002). However, during mid premolt 263	  
the animal makes a decision to complete molting preparations without delay. The YO transitions 264	  
to the committed state and becomes insensitive to MIH (Chang and Mykles, 2011; Nakatsuji et 265	  
al., 2009). Molting cannot be suspended by limb bud autotomy (Mykles, 2001; Yu et al., 2002). 266	  
YO commitment appears to involve Gl-Mstn, an activin-like peptide expressed in the YO (Fig. 3; 267	  
Das et al., 2016). The increase in Gl-Mstn mRNA level coincided with YO activation during the 268	  
first 3 days post-ESA, followed by a large decrease at 7 days post-ESA (Fig. 4C). Activin 269	  
receptor antagonist SB431542 caused a delayed decrease in hemolymph titer in ESA animals 270	  
between 7 and 14 days post-ESA (Fig. 2A). SB431542 had no effect on the initial increase in 271	  
hemolymph ecdysteroid titer at 1 and 3 days post-ESA, indicating that TGF-β signaling is not 272	  
required for YO activation. However, the delayed effect of SB431542, as well as the prolonged 273	  
effect of rapamycin (Fig. 1), suggest that YO activation is prerequisite for YO commitment. The 274	  
prolonged effect of SB431542 was probably due to its precipitation at the injection site, as the 275	  
compound, like rapamycin, has low solubility in aqueous solutions. Direct targets of the activin 276	  
signaling pathway are the mTOR signaling genes and Gl-EF2, as SB431542 blocked the increase 277	  
in Gl-mTOR and Gl-Akt mRNA levels (Fig. 2C, E) and lowered Gl-Rheb and Gl-EF2 mRNA 278	  
levels (Fig. 2B, D). The up-regulation of mTOR signaling genes precedes the increase in 279	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ecdysteroidogenesis of the committed YO at Day 7 post-ESA (Fig. 2A). These data are 280	  
consistent with the hypothesis that the activated YO synthesizes Gl-Mstn for the mid premolt 281	  
transition and a sustained constitutive increase in ecdysteroid synthesis that is mTOR-dependent.  282	  
Activin/Smad signaling may alter expression of genes that determine the committed YO 283	  
phenotype. Possible downstream targets are genes involved in ecdysteroidogenesis and MIH 284	  
signaling. The up regulation of Halloween genes, such as phantom, is associated with increased 285	  
ecdysteroid biosynthesis in the YO (Asazuma et al., 2009) and insect PG (Iga and Kataoka, 286	  
2012). Down regulation of MIH signaling genes or up regulation of PDEs would reduce 287	  
sensitivity to MIH (Chang and Mykles, 2011; Nakatsuji et al., 2009). In insects, activin/Smad 288	  
signaling confers competency to the PG to respond to PTTH to trigger the metamorphic molt 289	  
(Gibbens et al., 2011; Pentek et al., 2009; Rewitz et al., 2013). These results are the first 290	  
evidence that an activin-like TGF-β peptide regulates YO ecdysteroidogenesis. As in the insect 291	  
PG, it may function to alter sensitivity of the YO to neuropeptides. 292	  
 293	  
5. Conclusions 294	  
Three signal transduction pathways mediate two critical transitions in the molt cycle of G. 295	  
lateralis. A working model, which incorporates data from this study and from a previous study 296	  
(Abuhagr et al., 2014b), is illustrated in Figure 5. MIH, via cyclic nucleotide second messengers, 297	  
maintains the YO in the basal state (Chang and Mykles, 2011; Covi et al., 2009; Webster, 2015). 298	  
The transition of the YO from the basal to the activated state is initiated by a reduction of 299	  
circulating MIH (Chang and Mykles, 2011). YO activation involves mTOR-dependent protein 300	  
synthesis required for cellular growth and increased ecdysteroidogenic capacity, as rapamycin 301	  
inhibits YO ecdysteroidogenesis in vitro (Abuhagr et al., 2014b) and in vivo (Fig. 1). A closer 302	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examination of the effects of rapamycin on hemolymph ecdysteroid titer compared to the effects 303	  
of ESA on mTOR signaling gene expression in control animals suggest that mTOR up regulation 304	  
involves both transcriptional and posttranslational mechanisms. Initial mTOR activation is likely 305	  
regulated post-translationally, as the YO is highly sensitive to rapamycin in vitro (Abuhagr et al., 306	  
2014b) and rapamycin blocked the increase in ecdysteroid titer by 1 day post-ESA (Fig. 1). 307	  
mTOR is activated by protein phosphorylation and by Rheb through inhibition of the tuberous 308	  
sclerosis complex (Ekim et al., 2011; Heard et al., 2014; Huang and Manning, 2008). mTOR 309	  
activation was followed by increased mRNA levels of mTOR signaling genes at 3 days post-310	  
ESA (Fig. 2). mTOR regulates gene expression, either directly or indirectly, by phosphorylation 311	  
of transcription factors, such as STAT3 (Laplante and Sabatini, 2013). mTOR activity may also 312	  
be required for the transition of the YO from the activated to the committed state, as rapamycin 313	  
blocked or delayed the large increase in ecdysteroid titer at 14 days post-ESA (Fig. 1).  314	  
The model proposes an autocrine regulation by an activin-like peptide that drives the 315	  
differentiation of the YO to the committed state (Fig. 5). A potential candidate is Gl-Mstn, which 316	  
is expressed in YO, muscle, and other tissues (Fig. 3; Covi et al., 2008; Das et al., 2016). The 317	  
timing of the peak in Gl-Mstn mRNA level (Fig. 4C) and the SB431542-induced drop in mTOR 318	  
signaling gene mRNA levels at Day 3 and hemolymph ecdysteroid titer at Day 7 (Fig. 2) are 319	  
consistent with the following mechanism: (1) upon activation, the YO synthesizes and secretes 320	  
Gl-Mstn peptide through the combination of increased Gl-Mstn mRNA and increased mTOR-321	  
dependent translation; (2) Gl-Mstn peptide binds to the activin receptor, which phosphorylates 322	  
and activates R-Smad; and (3) R-Smad binds to Co-Smad and the transcription factor complex 323	  
translocates to the nucleus and sustains or up regulates genes (e.g., Gl-EF2, Gl-mTOR, Gl-Rheb, 324	  
and Gl-Akt) required for transitioning animals from stage D0 to D1 between 7 and 14 days post-325	  
15 
	  
ESA. The model is consistent with the roles of mTOR and activin/Smad signaling in regulating 326	  
ecdysteroidogenesis in the insect PG (Danielsen et al., 2013; Rewitz et al., 2013; Yamanaka et 327	  
al., 2013). Current work is using RNA-Seq technology to uncover the gene networks underlying 328	  
the dynamic changes in YO properties over the molt cycle.  329	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Abbreviations: Gl, G. lateralis; F, forward; R, reverse; Akt, protein kinase B; EF2, elongation 463	  
factor 2; Mstn, myostatin-like factor; mTOR, mechanistic target of rapamycin; Rheb, Ras 464	  

















   
Gl-EF2 F1 TTCTATGCCTTTGGCCGTGTCTTCTC 227 Gl-EF2 R1 ATGGTGCCCGTCTTAACCA 
Gl-Mstn F1 GCTGTCGCCGATGAAGATGT 118 Gl-Mstn R1 GGCTGGGGACCTCAATCCCGT 
Gl-mTOR F2 AGAAGATCCTGCTGAACATCGAG 159 Gl-mTOR R2 AGGAGGGACTCTTGAACCACAG 
Gl-Rheb F1 TTTGTGGACAGCTATGATCCC 119 Gl-Rheb R1 AAGATGCTATACTCATCCTGACC 
Gl-Akt F2 AACTCAAGTACTCCAGCGATGATG 156 Gl-Akt R1 GGTTGCTACTCTTTTCACGACAGA 
Gl-s6k F2 GGACATGTGAAGCTCACAGACTTT 239 Gl-s6k R1 TTCCCCTTCAGGATCTTCTCTATG 
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Figure Legends 474	  
Fig. 1. Effect of mTOR inhibitor rapamycin on hemolymph ecdysteroid titers in G. lateralis in 475	  
vivo. Animals were eyestalk-ablated at Day 0 and injected with a single dose of rapamycin (~10 476	  
µM final hemolymph concentration) or equal volume of DMSO (~0.1% final hemolymph 477	  
volume). Data presented as mean ± 1 S.E. (n = 5-8). Asterisks indicate means that were 478	  
significantly different (P < 0.05) between control and rapamycin at the same time point. Letters 479	  
indicate significant differences in the means within a treatment (upper case for control; lower 480	  
case for rapamycin); means that were not significantly different share the same letter.  481	  
 482	  
Fig. 2. Effects of activin receptor antagonist SB431542 on YO ecdysteroidogenesis and gene 483	  
expression in G. lateralis in vivo. Intact and eyestalk-ablated animals were injected with a single 484	  
dose of SB431542 in DMSO (~10 µM final hemolymph concentration) or DMSO (~0.1% final 485	  
hemolymph concentration) at Day 0. (A) Hemolymph ecdysteroid titer. Transcript levels of (B) 486	  
Gl-EF2, (C) Gl-mTOR, (D) Gl-Rheb, (E) Gl-Akt, and (F) Gl-s6k were quantified by qPCR. Data 487	  
are presented as mean ± 1 S.E. (sample size for each treatment: Day 0, n = 8; Days 1, 3, and 7, n 488	  
= 5; Day 14, n = 7). Asterisks indicate means that were significantly different (P < 0.05) between 489	  
control and SB431542 at the same time point. Letters indicate significant differences in the 490	  
means within a treatment (upper case for control; lower case for SB431542); means that were not 491	  
significantly different share the same letter. Means without letters were not significantly different 492	  
at all time points within a treatment. Gene expression in intact animals was not measured (see 493	  




Fig. 3. Tissue expression of Gl-Mstn and Gl-EF2. End-point RT-PCR was used to qualitatively 496	  
assess mRNA levels of Gl-Mstn and Gl-EF2 in gill (G), heart (H), heptatopancreas (HP), midgut 497	  
(MG), hindgut (HG), claw muscle (CM), thoracic muscle (TM), testes (T), thoracic ganglion 498	  
(TG), Y-organ (YO), and eyestalk ganglia (ESG). 499	  
 500	  
Fig. 4. Effects of eyestalk ablation on hemolymph ecdysteroid titer (A) and Gl-EF2 (B) and Gl-501	  
Mstn (C) mRNA levels in G. lateralis YO. Animals were ES-ablated and received a single 502	  
injection of DMSO (~0.1% final concentration) at Day 0. Data are presented as mean ± SEM 503	  
(Day 0, n = 8; Days 1, 3, 7, and 14, n = 10; Day 5, n = 9). Upper case letters indicate significant 504	  
differences in the means. Means that were not significantly different share the same letter; the 505	  
mean without a letter (7 days post-ESA) was significantly different from all other means. 506	  
Abbreviations: EF2, elongation factor-2; Mstn, myostatin-like factor. 507	  
 508	  
Fig. 5.  Proposed model for the regulation of the YO by MIH, mTOR, and TGF-β signaling 509	  
pathways. Pulsatile release of MIH maintains the YO in the basal state and the animal remains in 510	  
intermolt. Decreased MIH release triggers mTOR-dependent YO activation, which is inhibited 511	  
by rapamycin. The activated YO produces an activin-like TGF-β peptide (Mstn), which drives 512	  
the transition to the committed state in mid premolt. SB431542, an activin receptor antagonist, 513	  
blocks the transition of the YO from the activated to committed state. 514	  
  515	  
24 
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Figure 4 524	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